Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medicago, a biotechnology company, and Cellectis plant sciences, have entered a research agreement to jointly improve therapeutic proteins expressed from tobacco leaves, with the help of nuclease technology.
Subscribe to our email newsletter
Cellectis manufactures DNA scissors called nucleases that can cut precise DNA sequences allowing for the creation of a wide range of specific tools to modify a target gene.
Medicago chief scientific officer Louis-Philippe Vezina said the company seeks to work with Cellectis plant sciences to assess their nuclease technology for use in developing biosimilar products.
"This tool has the potential to hasten the expansion of our platform towards the production of a wider range of therapeutic proteins including biosimilars, and complement our existing tools for the control of protein glycosylation," Vezina added.
Cellectis plant sciences CEO Luc Mathis said the company is applying its technology for use in plants to produce potential products for human health benefit.